Market Overview

Bristol-Myers Presents 4 and 5-Year Survival Data for YERVOY in Treatment-Naïve and Previously-Treated Metastatic Melanoma

Bristol-Myers
Squibb Company (NYSE: BMY) today announced four- and five-year
survival rates based on long-term follow up from Phase 3 and Phase 2
YERVOY® (ipilimumab) clinical trials in patients with
treatment-naïve and previously-treated metastatic melanoma. The data
were presented at the ESMO 2012 Congress (European Society for Medical
Oncology). (Abstract #1127 and 1116.)

In the Phase 3 trial (024), patients who had not previously received
treatment for metastatic melanoma (n=502) were randomized to receive
either the investigational dose of YERVOY 10 mg/kg in combination with
dacarbazine (DTIC, 850 mg/m2) or DTIC alone. Long-term
follow-up from this study demonstrated that treatment with YERVOY plus
DTIC resulted in a four-year survival

See full press release

Posted-In: News Guidance Management

 

Related Articles (BMY)

Around the Web, We're Loving...

Get Benzinga's Newsletters